ClinicalTrials.gg
Status unknownNCT03190876Updated May 3, 2019

Seroma Prevention After Body Contouring Procedures

An interventional study of Variable drain usage in Seroma, Abdominoplasty and Complication of Surgical Procedure, sponsored by University of Regensburg. Status unknown at 1 site in Germany. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-03.

Sponsored by University of Regensburg · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2017, registered Jun 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

With a prevalence of up to 25%, seroma formation is among the most common complications of body contouring procedures such as abdominoplasty. Small amounts of fluid are reabsorbed by the body spontaneously, however, larger seroma volumes need to be evacuated via puncture aspiration to prevent wound healing disturbances and infection, leading to major patient discomfort and a prolonged hospital stay. There is increasing controversy regarding the efficacy of surgical drains in seroma prevention. This study compares the incidence rate of seroma in three study arms with different usage of drains.

02

Conditions studied

  • Seroma
  • Abdominoplasty
  • Complication of Surgical Procedure

Browse trials for

Keywords

  • Drain usage
03

In context

Seroma

101 studies on the registry are indexed under Seroma; 22 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 92 interventional studies indexed under Seroma.

Browse Seroma studies →

Lead sponsor

University of Regensburg is the lead sponsor of 71 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All full-aged patients requiring body contouring procedures in our department who provide oral and written indicating that they agree to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Minors or patients with a designated health care proxy, revision surgeries, morbid obesity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • No intervention
    Suction drain

    Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7

  • Active comparator
    Passive drain

    Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7

    Procedure: Variable drain usage

  • Active comparator
    No drain

    Conventional body contouring procedure, no application of drains

    Procedure: Variable drain usage

Interventions

  • ProcedureVariable drain usage

    Influence of drain usage on seroma formation rate

06

What researchers measure

Primary outcomes

  1. Rate of seroma formation

    As primary outcome this study measures the rate of seroma requiring evacuation via puncture aspiration (fluid retention \> 20 cc) in each group.

    Time frame: Weekly follow-up until postoperative week 6.

07

Study locations

1 of 1 sites recruiting
  • Department of Plastic Surgery, University Hospital of Regensburg
    Regensburg, Bayern 93053, Germany
    Recruiting
    • Lukas Prantl, Prof. Dr. Dr. · Contactlukas.prantl@ukr.de · 0049 941 782 3110
    • Alexandra Anker, Dr. med. univ. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2017 (actual). Primary completion is estimated for Mar 2022, 60 months after the start.

Of 43 non-industry interventional studies with no phase under Seroma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 65. This study's planned 60 months is above that.

Counting every sponsor, half of 44 studies reached it within 34 months; a quarter within 17 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2017
First posted
Jun 19, 2017
StartActual
Mar 1, 2017
Primary completionEst.
Mar 1, 2022
CompletionEst.
Mar 1, 2022
Last update
May 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03190876
Lead sponsor
University of Regensburg
Responsible party
Dr. Alexandra Anker (Principal Investigator, University of Regensburg) — Principal investigator
First posted
Jun 19, 2017
Start date
Mar 1, 2017
Primary completion
Mar 1, 2022 (estimated)
Completion
Mar 1, 2022 (estimated)
Last update
May 3, 2019

Study contacts

Alexandra Anker, Dr. med. univ.
Contact
aanker@caritasstjosef.de
0049 941 782 3110

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion